

## ORIGINAL ARTICLE

# Comparative Efficacy of Roflumilast in Moderate to Severe COPD versus Placebo

1Dr Asma Qibtia, 2Dr. Aftab Rabbani, 3Mohib Ali, 4Qamar Abbas, 5Mirza Muhammad ayub baig, 6Faiza Maqsood, 7Kashif Lodhi

<sup>1</sup>Internal medicine, Medical unit 3, Allied Hospital Faisalabad

<sup>2</sup>Internal medicine, Sharif Med & Dental College Lahore. Assoc.prof <sup>3</sup>PIMS <sup>4</sup>PIMS Islamabad <sup>5</sup>Jinnah hospital Lahore. <sup>6</sup>UHS Lahore <sup>7</sup>Department of Agricultural, Food and Environmental Sciences. Università Politénica delle Marche Via Brece Bianche 10, 60131 Ancona (AN) Italy

### Background:

COPD, or chronic obstructive pulmonary disease is a type of condition that has both and its very hard to control all around it will escalate Opcode over time. Another feature that sets it apart from other conditions, is an irreversible airflow restriction. Chronic obstructive pulmonary disease (COPD) results from years of cumulative exposure to noxious particles and gases most often tobacco smoking, resulting in chronic inflammation in the lungs. This inflammation arises due to environmental toxins that are being accumulated. In a cascading result to the inflammation, often there is a change in shape and narrowing of typically an airway. Damaged areas of the lung can develop emphysema, which is characterized by a loss of elasticity and deterioration in its condition. This, in turn, results in the killing of certain regions if the lung. This is the reason why when people feel this kind of symptoms, they tend to suffer from breathing shortage. On-going inflammation also leads to blood clots, (think heart attacks) and create more mucus leading the airways not working well. This continues until it causes the airways to be fully blocked. Such pathological abnormalities, associated with systemic inflammation are likely to additionally exacerbate comorbid states such as cardiovascular disease and muscle wasting disorders [4].

The cellular level this process includes neutrophils, macrophages and T lymphocytes among the cells leading to chronic inflammations. All of these cells are involved in the process . This process also recruits mediators such as cytokines, chemokines and proteases etc. Furthermore, these mediators also prolong the inflammatory cascade as they serve to propagate inflammation well into a tissue 9. This disruption of redox balance is a major source for oxidative stress in the lungs and plays an important role at the beginning, inducing inflammation and tissue injury resulting finally to fibroproliferative processes . Moreover, oxidative stress is an important mechanism in the pathogenesis of FMD.

Roflumilast is a member of an entirely new class of medications, called selective phosphodiesterase-4 (PDE 4) inhibitors and specifically targets the underlying inflammation which causes COPD. One of the molecules involved in these pathways is cyclic adenosine monophosphate (cAMP), an enzyme that helps degrade cAMP, such as PDE-4. The main mechanism of action is as a PDE-4 inhibitor and the level necessary to affect most asthmatics should have little effect on circulating cytokines such anti-tumor necrosis factor. Thereby, release of pro-inflammatory cytokines and chemokines into the peripheral bloodstream is reduced. It consequently has an inhibitory effect on mucus secretion and also acts as a natural mechanism of inflammation in chronic inflammatory cascades of the airway. Finally, roflumilast has been shown to have antifibrotic properties that could also contribute to an indirect protection of the airways from structural remodelling and fixed airflow limitation.

Roflumilast has been investigated in several phase 3 research and clinical trials for treatment of chronic obstructive pulmonary disease (COPD) albeit with varied results. The attenuation of proinflammatory biomarkers in sputum along with a trend towards better lung function scores tend to be beneficial by way of roflumilast within the first cycle involving clinical trials. Because of this, second-line therapy in the phase III trials -- such as that done by Calverley and colleagues -- was factored into play. Bateman et al., published studies investigating the impact of roflumilast in severe or very severe COPD and Fabbri et al. that described Roflumilast added to salmeterol/fluticasone were pooled (five trials) for this aim [5].

The trials demonstrated that roflumilast significantly increased pre-bronchodilator forced expiratory volume in one second (FEV1) compared with placebo. In addition, roflumilast was linked to decreased rates of COPD exacerbations-especially among those with a background of frequent exacerbations and chronic bronchitis. These changes were maintained for 52 weeks, suggesting a long-term maintenance therapy capability with roflumilast in COPD. Also, roflumilast was well-tolerated overall with the most frequent adverse events seen in this study were gastrointestinal symptoms (diarrhea and weight loss), which could be managed by a high percentage of patients [6].

In contrast, the overall benefit-risk ratio of roflumilast has been questioned in other studies despite this seemingly positive result. The treatment was stopped in few cases for side effects like weight loss and gastrointestinal distress. Furthermore, the treatment effect of roflumilast appears to be restricted entirely on those with CB and a history of exacerbations suggesting that its benefit may not be generalizable well beyond this specific patient population suffering from COPD. These considerations reinforce the importance patient selection as well monitoring when considering roflumilast in clinical practice.

As roflumilast, a PDE4 inhibitor is known to reduce exacerbation rates and also provides clinically significant benefit in terms of weight loss; we hypothesize that compared with placebo more patients on Roflumilast will have an improvement in lung function. The primary research question is the treatment specific magnitude of change in pre-bronchodilator FEV1 and rate exacerbations over a fixed time period among patients with COPD treated for some duration by roflumilast. Secondary objectives include assessment of the effects of roflumilast on other clinical outcomes (quality-of-life scores, hospitalization rates), safety and tolerability [7].

Here, we will attempt to incorporate further detail and establish the hierarchy of clinical research at which point in therapy with this review regarding roflumilast COPD management. This will help broaden our understanding on the effectiveness of anti-inflammatory therapy in chronic obstructive pulmonary disease, particularly in these 'more severe' phenotypes with increased risk for exacerbations and progression. Our study will also provide the clinical algorithm for management of COPD and establish treatment guidelines that might help health care professionals to deliver a more personalized therapy in moderate-to-severe-COPD admissions leading to better patient outcome with quality-of-life.

**Keywords:** COPD , Roflumilast , Lung Function , Quality of Life , Exacerbations.

## **INTRODUCTION:**

Long-term respiratory distress (generally the two kinds of Chronic Obstructive Pulmonary Disease - COPD) plus airflow limitation, is a category of lung disease characterised by long duration problems with very little air External Usually effects in slower

turn on discursive oxygen as well as due to running bones are Soft-Bill five years As above causes some ear obstruction or airs. It presents most commonly Early fourpence since allergen gas and particle milk lifetime or for class for cycling fullutations. Materials and Methods Background Chronic

obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema send to an unclear heterogeneous group of disorder with similar clinical symptoms but diversity pathology due in part by genetic influences (). A condition with symptoms of persistent coughing, sputum production and breathlessness at times. It is established that this disease triggers reduced quality of life, and consequently an increased burden on healthcare due to the disabling symptoms [1]

It is already well shown that it can be very difficult to control therapy by the time more severe bronchitis and particularly emphysema have begun, whereas milder forms of the disease -- say mild to moderate COPD--may indeed respond better than expected to aggressive treatments. Abstract Patients in these stages experience exacerbations, characterized by an acute worsening of respiratory symptoms requiring a change or increase in treatment. Each of these exacerbations can cause a dramatic decline in lung function, increased number of hospital admissions and higher mortality. In people with moderate and severe chronic obstructive pulmonary disease (COPD), the goal of treatment is to improve symptoms, exercise capacity and reduce exacerbation frequency.

It is unclear whether adding roflumilast, a selective phosphodiesterase-4 (PDE-4) inhibitor to the combination of inhaled corticosteroids also add benefit due specifically reducing exacerbations [18]. This analysis was performed within two phase III trials. This is PubMed. Roflumilast, a Phosphodiesterase-4 (PDE-4) inhibitor decreases inflammation in the airways and is used to treat COPD. Particularly suitable for acute patients, chronic bronchitis too. Roflumilast, inhaled medications have poor compliance as well more patients will likely be on Roflumilast orally since route of administration can do better than bronchodilation [2].

The object of this study is to evaluate roflumilast as therapy for patients with moderate-to-severe COPD compared with placebo The trial was designed in an effort to homogenize the comparison between

Roflumilast and placebo on lung function exacerbations rate, other aspects most advanced treatment. We need data like what was provided in this paper to know where roflumilast may or many not fit when treating COPD.

Combination inhalers containing a bronchodilator and corticosteroid are used in chronic obstructive pulmonary disease (COPD) as well. Beta-agonists and Anticholinergics From this group They work because they cause the muscles along your airways to twitch, making you feel relaxed again. Inhaled corticosteroids reduce exacerbations by decreasing airway inflammation (and therefore both frequency and severity of them) Regrettably, despite the unparalleled scientific progress in pharmacological research and drug development that has been realized over the past 60 years, all current therapies are beset with some limitation extent - of either toxicity or transient effect (tachyphylaxis) along side unsurpassed challenges to achieving adherence itself mendacity with inhaler compliance. This highlights the fact that better drugs need to be formulated because these treatments do not more than enough for those patients [3].

### **Study Design**

This was a multicentre, randomized placebo-controlled trial to study the efficacy of roflumilast in moderate-to-severe COPD. The gold standard for assessing the effectiveness of interventions is said to be randomized controlled trials. This is because they help to reduce bias and provide a direct comparison with the control intervention. Because participants in this study were randomized to roflumilast or placebo arms, any differences in clinical outcomes between these two genotypes could only theoretically be due to the intervention and not anything ancillary Also relevant is that prior studies have established distinct biological effects of each ABCC1 IVS2+16A>G genotype3. [8]

### **Overview of Study Design**

The study was performed at multiple centres to increase the generalizability of the results. Again,

the study was unheard of because it began with a double-blind approach where neither the participants nor even researchers knew who got what treatment. This design minimizes the risk of bias in outcome evaluation. It used a parallel-group design, with roflumilast or placebo in the second group. Because the 12-month time frame of this study offered potential for both short- and long-term effects, it was a valuable trial.

#### **Intervention and Control Conditions**

##### **Intervention: Roflumilast**

Roflumilast is a selective PDE-4 inhibitor that exerts its activity by increasing intracellular cyclic adenosine monophosphate (cAMP) levels in inflammatory and structural cells. High cAMP levels inhibit the inflammatory response, a cardinal component of COPD pathophysiology. Roflumilast reduces inflammation and, this way, it improves lung function by decreasing the number of times that people experience acute exacerbations (acute episode leading to hospitalizations), which might have a further negative impact on lung health.

Those in the roflumilast group were given a once-daily dose of 500 micrograms (mcg) of the drug. The treatment was oral, single tablet dosing. The regimen with roflumilast at this dose was selected on the basis of prior clinical trial data, which validated safety and efficacy. Compliance was monitored by having participants keep a medication diary and bring their pill bottles to each study visit for counts

##### **Control: Placebo**

The placebo group was administered an identical tablet that included a neutral product without drug. The placebo tablets were identical to the roflumilast tablets in appearance and taste, also aimed at maintaining blinding. The placebo group also received one tablet daily at the same time as the roflumilast tablets. The study was double-blind, and unblinding controls ensured that matching placebo tablets could not be distinguished from the active drug.

##### **Randomization and Blinding**

The subjects were randomly divided into two groups, one received roflumilast and the other was put on placebo treatment using a computer-generated randomization sequence in double-blind fashion. Stratifying by randomization of research centres, it guarantees uniform distribution in which equal participants are allocated to each treatment group and with the same number. This is done to minimise the effects of specific centre variances on outcomes [9].

Because roflumilast and placebo tablets both were contained in identical packaging, patients could be maintained blinded to treatment throughout the study. Treatment assignments were concealed, but the group of participants receiving each arm and to which specific outcome evaluations study personnel had been deputed prespecified openly. Unblinding was allowed only in cases of a medical emergency, which warranted the intervention to be disclosed beforehand for appropriate participant management.

##### **Study Population**

Adults 40 years old or older who met GOLD criteria for moderate to severe COPD were eligible. Inclusion criteria were post-bronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) between of the predicted normal and more than with a history of two or more exacerbations during the past year. Criteria for exclusion contained other major respiratory diseases (e.g. asthma), a recent track record of using oral corticosteroids or an allergen hypersensitivity to 4TH inhibitors

The primary and secondary outcomes

Endpoints included the prebronchodilator change in FEV<sub>1</sub> at end of study from baseline. FEV<sub>1</sub> is a key measure of lung function, and it evaluates the extent to which airways can carry air. The variation in the LLN or % predicted) FEV<sub>1</sub> values reflects how open airways are and hence, better function.

Reported endpoints other than exacerbation rate Symptoms: St. George's Respiratory Questionnaire and validated quality of life (QoL) measures, safety outcomes serious adverse events [SAEs], deaths),

tolerability Endpoints Definition Exacerbations Deterioration in COPD symptoms requiring use antibiotic or systemic corticosteroids Quality-of-life evaluations conducted during the trials generated specific data on how treatment affected the day-to-day and overall well-being of each participant. Safety and were assessed via adverse events, laboratory studies, and physical examinations.

#### Collect and Monitor the Data

Participants also had to appear on a schedule, such as for the baseline visit (the beginning of study), three months in, six months in etc. Over these visits, lung function was assessed in terms of opened circuit spirometry to measure FEV1 and quality of life questionnaires were also completed by participants. The study investigators went through the participant diaries at each of their visits and reviewed what was reported about exacerbations. Adherence to medication was based on counting the number of pills taken during clinic visits, patient diaries provided by participants [10].

Safety assessment: Safety assessments included laboratory tests (serum chemistry and hepatic function), ECGs, and vital signs collected from the patient. Adverse events were recorded by frequency, and an assessment of the severity was then performed according to its relationship with the study drug. Participants were reminded to report any new or worsening SAEs immediately.

#### Statistical Analysis

The primary analysis also used an ANCOVA model to compare the change in pre-bronchodilator FEV1 with roflumilast versus placebo, adjusting for baseline values of this parameter. A Poisson regression model was used for rate of exacerbations, while mixed-effects models were used to compare quality of life scores. Safety data were summarized descriptively, and adverse-event rates were compared between groups using chi-square tests.

#### Ethical Considerations

The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained

before any study tasks were undertaken. The study protocol was approved by the institutional review board at each participating centre.

#### Population and Sample Size

Valid definitions of the disease population and a large enough sample size are necessary requisites when designing an informative trial to compare clinical efficacy outcomes in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with roflumilast versus placebo. Work of setting the trustworthiness, accuracy and even whether or not it is transferable - all these are joints. This section explains the criteria used to sample participants, and how we determined that our chosen sample size would be sufficient in order to conduct research [11].

#### Inclusion Criteria

In these inclusion criteria, we deliberately defined mild-to-moderate airflow obstruction to select a population more likely with moderate or severe COPD in which this would be generalizable. Subjects were adults aged 40 years or older based on the results of a previous study. This age cutoff was included as COPD, the main disease of interest in this study largely affects older adults seen and younger participants would be less likely to have established diagnosis of moderate-severe COPD. In addition, the fact that at least 40 years and older ">16 Following Pounding voided a spirometry cut-off point> masses of COPD patients helps to standardize such real-life mimics into clinical practice.

Significant exclusion criteria also included moderate-to-severe COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition). Based on post-bronchodilator forced expiratory volume in one second (FEV1) % predicted, severity is graded. Level of forced expiratory volume in 1 second (FEV1): participants had to have a post-bronchodilator FEV1 70% to 80% predicted for the study. These patients have severe disease and benefit the most from anti-inflammatory agents and exacerbation prevention.

In addition, patients could not have had more than one exacerbation in the preceding year. Patient populations study to nexus new therapeutic approaches for COPD in clinical and translational research must be with patients who have a history of exacerbations because frequentness is typical of more serious disease, as well worsened prognosis. History of Exacerbations: Was confirmed by medical records and participant self-report during the screening visit

A further mandatory inclusion criterion was the diagnosis of chronic bronchitis, characterised by cough and sputum production on most days for at least a fraction (three consecutive months per year) of 2 years. Since chronic bronchitis is the most overemphasized of all COPD phenotypes that need mucus production and characteristic increase in inflammation, for obvious reasons we opted to study a distinct subgroup if indeed anti-inflammatory action contributed to roflumilast.

#### **Exclusion Criteria**

Support was repeated to ensure the safety and scientific legitimacy of all individuals critical for proper implementation of exclusion criteria. Eligibility criteria were limited to exclude patients with known other clinically significant respiratory diseases (including but not restricted to chronic obstructive pulmonary disease, asthma, bronchiectasis and interstitial lung fibrosis) associated with a substantial risk of pneumonia. This noise in the results would add yet more variables concerning lung function and inflammation which are practically impossible to distinguish from any change in outcomes due either intervention or placebo.

We also excluded those patients who had taken any systemic corticosteroids or other immunosuppressive drugs within 4 weeks from the present study. These drugs are able to modulate inflammation and lung function such that a property of the study medication may no longer be measurable. We wanted to exclude recent treatments that may alter the outcomes,

To minimize the risk of complications and potential study related interactions, participants who had severe cardiovascular disease that was unstable or were NYHA IV heart failure status as well as those with recent (within 6-months) myocardial infarction/post-myocardial revascularization/coronary intervention ((PCI)/coronary artery bypass grafting(CABG)), acute decompensated angina were also excluded. The emergency of the event was another reason for not recruiting intensively in this population: The findings were less likely to be masked by an acute cardiac event, which are prevalent among COPD patients and whose incidence is higher than other chronic conditions when they comorbidities between each other [12].

Fact The fact that roflumilast has the potential for psychiatric side effects meant it was unsafe to study in these patients due to their high suicide risk, and they were excluded from participating. Participants who had significant weight loss in the past or were suffering from malnutrition also was ruled out, as would participants with pre-existing states that may confound results (and because of roflumilast possible adverse effects-- among which is weightless).

Due to the fact there was an issue about baby or a foetus in utero potential risk, researchers removed pregnant and lactating women from this study. Women of childbearing potential (WOCBP) must have been using two forms of effective contraception during the study. A standard contraindication to medical testing likely for the health and safety related with unborn infant and stillborn.

#### **Sample Size Determination**

The study will need power to be able to detect clinically relevant differences between the roflumilast and placebo arms, so choosing an appropriate sample size is key. The study was designed to calculate the sample size based on assumptions: with regard to the primary outcome measure (change from baseline in pre-

bronchodilator FEV1, measured as a percentage of predicted normal values); anticipated treatment differences between groups; variability associated with our key efficacy variable itself and expected levels of statistical power and significance.

The main end point was the change from baseline in prebronchodilator FEV1 at EoT. According to previous studies we anticipated a clinically meaningful difference in FEV1 between roflumilast and placebo of ~ 100 ml. The sample size calculation was based on a change in FEV1 from baseline test of 200 millilitres (mL), as similar variability has been observed within COPD trials, generally accepted to represent that which is considered clinically important by patients and/or physicians.

Statistical power was intended to increase at 80%. Statistical power refers to the probability of detecting a difference between two independent samples should one actually exist. The power of 80% is a number often used to strike the balance between failing to detect a true effect (type II error) and being reasonably confident that you will be able to find enough people for your trial.

A significance level of 0.05 implies a risk of Type I error (i.e., finding difference where there is none). This has meant balancing false positives vs true effects, and using a  $p < 0.05$  as the threshold for statistical significance in such tests is common practice (putting this into context...)

This corresponded to a prospective minimum requirement of ~ 250 per group (for an effect size of detecting difference in FEV1 of 550 ml at  $p = 0$ . MockMvc et al. To allow for anticipated dropout and non-adherence a further 10% was recruited resulting in either group having both an enrolment total of 275 or as displayed by Clinical trials.

The target population to be sampled of methodological issues including exacerbated COPD raters, quality-of-life measures in patients with COPD were also considered. While the sample-size calculation was grounded on changes in PFT measures, powered to detect differences for these outcomes as well were deemed important.

Numerous outcomes were taken into account in the sample size calculation for this study, hence ensuring that findings will be reliable and supportive or not of roflumilast efficacy [ 13].

#### Intervention

##### Roflumilast Dosage and Administration

The intervention cohort was administered Roflumilast, a specific phosphodiesterase-4 (PDE-4) inhibitor. The probe was related to a patient treated. Indication: Chronic Obstructive Pulmonary Disease (COPD) It has a dosage of 500 micrograms (mcg) one tablet per day for roflumilast. Oral 500 mcg/dOS once daily for intervention arm participants. The pills were intended to be taken with and without food, in an attempt to increase compliance by catering for both end of the spectrum from a pill once-a-day regimen point of view.

Design: Roflumilast is a selective oral phosphodiesterase 4 (PDE-4) inhibitor that increases intracellular cyclic adenosine monophosphate. This, in turn, produces an anti-inflammatory reaction in the faces of COPD. This is especially useful in breaking down the inflammation and mucus in the airway, which is a mandatory process to help treat Chronic Obstructive Pulmonary Disease (COPD). One of the mechanisms behind this action is decreased stimulation by acetylcholine, which correlates with an observed magnitude that seems clinically important (i.e. reductions in exacerbation rates, increases lung function) at doses previously well-documented to provide efficacy and acceptable safety profile aclidinium administered on COPD patients from clinical studies [4]. This was consistent with 500 mcg once daily dose in the current study.

##### Duration of Treatment

The follow-up period in the present study was nine months. The 60-week duration was chosen to reflect the time needed for a comprehensive evaluation of pulmonary function and exacerbation rates across both short- and long-term. The reason for 12 months

is because a very short period does not allow time for intervention effects on COPD symptoms and exacerbations to be seen, while too long may miss important seasonal variations in these outcomes. The follow-up period also provides more extensive safety data over a longer timeframe and the possibility to assess secondary endpoints, including quality of life.

In addition to the scheduled visits every three weeks, VPT participants had regular appointments at baseline, 3 months (6-week milestone visit [MV]), and again at a short-visit day ("last study" endpoint). These included clinic visits, lung function testing by standard spirometry and assessments of compliance/adverse events at study endpoints. Between the visits, participants were in contact with the study team regarding their COPD medications and symptoms [14].

### **Monitoring and Compliance**

Therefore, determination of roflumilast efficacy was based solely on post-treatment compliance in this study. The participants received a medication diary to document the daily dose of study drug used. It also required patients to visit the clinic for medication bottle and pill counts at each for study visit as well. Nevertheless, the approach did allow the research team to monitor compliance and intervene when problems with adherence arose.

Patients also received monthly study team telephone calls to foster adherence, troubleshoot possible side effects or medication administration problems and be available for other questions. This became a cue to action for them on their treatment and also allowed the study team follow-up calls- give support, motivation etc.

Case-by-case monitoring of adverse events occurred over this study period. Patients were asked to report the occurrence of any new symptom or worsening symptoms at follow-up. Checklist endoscopy with questionnaire and symptom review exam but without clinical indications; message: All study participants had any adverse clinical events

systematically reviewed at each visit by using checklist methodology plus a modification of symptoms reviewed in addition to examination/laboratory. This resulted in detecting any early signs of adverse events from roflumilast, hence pharmacovigilance.

### **Outcome Measures**

#### **Primary Endpoints**

The study's main endpoints were to enable an evaluation of the efficacy of roflumilast in improving lung function and reducing exacerbation rates among patients with stage II-IV COPD.

The primary end-point measure of lung function was pre-bronchodilator FEV1, which reflects all airway reactivity developed before visit 2 and should be less "contaminated" by the chronic remodelling and repair-induced phenomena. The FEV1 is a widely accepted measure of airflow obstruction and an obligatory end point in nearly all large-scale therapy trials for COPD. Spirometry including FEV1 was assessed at each visit, and subjects were refrained from the use of bronchodilators prior to testing (i.e. pre-bronchodilation). An increase in FEV1, is the evidence of reduced airway obstruction and better respiratory capacity, being crucial benchmarks for COPD therapeutics [15].

#### **Exacerbation Rate:**

The second key secondary endpoint was the rate of COPD exacerbations A COPD exacerbation was defined as an acute worsening of symptoms for which the patient started treatment with antibiotics, oral corticosteroids or were hospitalized. Participants were asked to keep a diary of exacerbation frequency, which was reviewed with the study team at each visit. Given that treatment-induced reductions in the rate of exacerbations are linked to prevention of disease progression, as well as enhancement health outcomes and resource use; reducing rates remains a target therapeutic objective for symptom management throughout COPD.

#### **Secondary Endpoints**

Additional results of the secondary endpoints further underscored roflumilast's effect on different aspects of COPD and patient quality of life.

**1. Hospitalization Rates:**

The researchers additionally documented hospitalization rates due to COPD exacerbations. This is an important outcome since hospital admissions lead to morbidity, healthcare costs and a poor quality of life. Using review of medical records from participants, hospitalizations were validated as well as differentiated acute exacerbations for other reasons.

**2. Adverse Effects:**

The study design emphasized safety and tolerability, of particular concern given the adverse events associated with roflumilast. Furthermore, all adverse events were systematically documented and graded in severity as well as relationship to study medication. In addition, we paid attention to the well-known adverse effects of roflumilast such as gastrointestinal complaints (e.g. diarrhea and nausea), as well weight loss. Emphasis was placed on the seriousness of adverse events (e.g. psychiatric symptoms interfering with overall welfare and participation in trial). Researchers also used routine laboratory testing including complete blood counts and liver function tests for this patient to determine potential subclinical side effects (since symptoms would likely not yet be clinically apparent).

**3. Other Respiratory Symptoms:**

Other respiratory symptoms including dyspnea (shortness of breath), cough, and sputum production in addition to FEV1 data as well as exacerbation rates were reported. The symptoms were evaluated according to different standardized scales, for example with the Modified Medical Research Council Dyspnea Scale (mMRC), which quantifies degree of breathlessness experienced by participants. These symptoms improvements lead to

better daily functioning and quality of life in COPD patients

**4. Exercise Capacity:**

The primary measure by which we assessed exercise capacity was the 6-minute walk test (6MWT), in meters. The test is an objective measure of functional status that has been demonstrated to be associated with morbidity and mortality in patients who suffer from COPD. The improvements in exercise capacity are reflection of an increase overall fitness and endurance, which has implications both for maintaining independence and reduce disability that influences the perceived HRQoL by patients with stable COPD.

In summary, the intervention and outcome measures of this study were well chosen to give a broad assessment on both efficacy and safety of roflumilast as treatment for moderate-to-severe COPD. This extensive monitoring and assessment approach enabled the researchers to capture both clinical outcomes as well as quality of life impacts, for valuable patient-sourced data on potential treatment benefits-and risks-among a group with this chronic condition. With extensive protocol adherence, the study sought to produce high-quality evidence for clinical practice and COPD management.

**Data Collection**

**Pulmonary Function Tests (like Spirometry)**

Spirometry has been held up as a major indicator of the efficacy and safety end points in roflumilast trials, showing significant improvement scores based on spirometric measures for moderate-to-severe COPD. To diagnose and monitor the progression of chronic obstructive pulmonary disease, spirometry - a test that measures how much air can be forcibly blown out after taking in a deep breath is also needed. Spirometry measures were done systematically in accordance with standardized test procedures which ensured that results could be compared across different study sites.

Spirometry Pre-BD and Post BD were done at the study initiation visit (Baseline), 3 months after

initiating medications, after every two-clinic visiting during scheduled on treatment clinical reviews till last follow-up (~every three monthly). Methods Pre-bronchodilator spirometry provided baseline assessment of the severity of airflow obstruction typical for COPD in forced expiratory volume in one second (FEV1), and lung hyperinflation by FVC which was reflected by FEV1/FVC ratio. Post-bronchodilator spirometry was utilized to test reversibility, and the results confirmed fixed obstruction [16].

We performed quality control to guarantee spirometry readings reliability and reproducibility. All of the subjects were trained on technique for using time so that there should be no such variability while they have undergone through tests. Technicians performed periodic calibration of spirometers using standard ATS/ERS calibration syringes as per manufacturer's standards and recorded environmental conditions including laboratory temperature for inclusion into interpretation algorithms.

#### Tracking of Flares, Exacerbations and Hospitalizations

Information on the clinical efficacy of roflumilast was also obtained from follow up for exacerbations and hospitalizations. We collected exacerbations (acute worsening of respiratory symptoms requiring treatment beyond routine care) systematically using participant diaries and confirmed at study visits. Participants reported a marked increase in their dyspnea, sputum production and severity of cough leading to early intervention for exacerbation management.

Hospitals in the trial also recorded episodes of exacerbations to assess effectiveness on roflumilast at reducing more severe COPD events that require hospitalization. For all exacerbation admissions a medical record and patient-reported data review was undertaken to confirm that these were due to disease-related events rather than other reasons (e. g.: not related with COPD).

Health-related Quality of Life (e.g., Questionnaires) Given that the assessments used for QoL, in relation to COPD were developed not too distant from a cadence close to this yet with small differences in focus than current health status it was believed they represent important measures capturing broader impact of living with stress beyond clinical outcomes when examining. COPD-related health status was the change from baseline to follow-up on detailed questionnaires like the St. George's Respiratory Questionnaire (SGRQ) or CAT - a clinical COPD assessment test capturing physical, emotional and social dimensions of disease-specific quality-of-life.

With the exception of fatigue being weighted less in patients on DMTs, these are scored as 0 for no impact to around 100 maximum impairment (asymptomatic) and all components carry an equal weight with a total score reflecting disease burden off treatment effects. A lower score means a better quality of life and symptom control. By contrast, symptom severity and functional impairment are the core ends of CAT (a simple tool), partly explaining its prominent contribution to improvement perceptions in clinically meaningful COPD management outcomes.

Standardized procedures were followed to deliver questionnaires, ensuring uniformity and veracity. Auto-administered questionnaires were either self administered by the participants or interviewer assisted; and data was inspected for completeness of responses before being scored. Score moves from one time point to another indicated the movement was due to either treatment response or disease progression so that they could be used for precision clinical decision-making and patient-centred care pathways.

#### Recording Adverse Events

A methodical protocol to document and follow these events was required in each phase of the study for a safer profile assessment with roflumilast. Adverse event was a treatment-emergent untoward medical phenomenon regardless of its causal relationship to

the study drug that manifested as symptoms, signs or abnormal laboratory findings at follow-up assessments.

The participants used study visits or designated contact points between the study visit to report adverse events. Detail for all events, including incidence, onset date and time of event (in UTC), duration of the episode in hours or days where applicable) severity measured as mild (+1) to moderate (+2)+ severe(+3); relationship to study medication acted on by central medical monitor. Roflumilast was associated with gastrointestinal side effects (e.g. diarrhea, nausea) weight loss and headache among its common adverse events.

We applied standardized definitions for grading severity of adverse events (e.g., CTCAE) which have implications both in clinical management and treatment decision-making. Immediate reporting of study-related SAEs was required if the event had resulted in death or hospitalization (or prolongation of existing hospitalisation) due to disability/incapacity that is persistent, significant/life-threatening; a congenital anomaly/birth defect; important medical event requiring intervention to prevent serious outcome/damage as per local regulatory guidance/sponsor standard operating procedures accompany treatment management.

#### Statistical Analysis

##### Primary and Secondary Endpoints Analysing Methods

A standard RCT-based analysis aiming to assess the effect of roflumilast compared to placebo on both primary and secondary endpoints was performed. Results of the Primary Outcomes: The primary outcomes evaluated were changes in pre-bronchodilator FEV1 and exacerbation rate. The statistical tests used were appropriate (t-test, Analysis of Covariance [ANCOVA]) to compare mean changes from baseline between roflumilast and placebo. That is instead of the analyses-(for which they adjusted for baseline covariables including age, smoking status)-reducing

confounding and enhancing rigor. In turn, with great relevancy for clinical interpretation and decision-making were effect sizes within 95 %CI that quantified the size of these treatment effects independently of p values.

Secondary Endpoints: Secondary endpoints were diverse and consisted of quality-of-life scores (e.g., SGRQ; CAT), hospitalization rates, or the incidence of adverse events. The results were reported using descriptive statistics (mean; standard>, >standard deviation), frequency distributions or inferential tests (chi-square test [6], and Wilcoxon rank-sum'>tests']>)). The use of subgroup analyses to assess treatment effects within covariate subgroups that are well defined a priori increases the level depth and clinical relevance, such as chronic bronchitis or smoking status.

#### Handling of Missing Data

Missing data strategies used to minimize bias while preserving statistical power. The missing data mechanisms were explored (e.g., MCAR, MAR in order to justify imputed information or sensitivity). These were applied to missing data using methods such as multiple imputation by chained equations (MICE) and allowed us to definitively estimate credible values for all partial information without eliminating internal variability or uncertainty. Findings were generally confirmed in sensitivity analyses that tested whether the results would have held under different assumptions about missing data, supporting their accuracy and generalizability. Reporting complete case analysis fully and clearly can help interpret study results, as well reproduce the findings of review studies be transparent for other researchers.

#### Subgroup Analyses

Individual subgroup analysis looked at the effect around a specific sort of participant (age. g chronic respiratory illness, preened amount regarding 500) because greater variability may also be potential throughout it contains particular populations which were hypothesised before you start to present

heterogeneity additionally atomic associations intrinsically sided significant over point value.). We tested this using statistical interactions of treatment assignment with subgroup variables and then used these to inform approaches for individualizing treatments.

More group-specific tests and adjustments to control for these may be performed (for instance interaction terms in regression models, stratified analyses) that would assist in the wider interpretation of results by limiting which questions could be asked depending on how you adjust your model. Conclusions from the subgroup analyses were clinically relevant in terms of directing disease-specific management strategies, allowing . [17]

## Results

### Baseline Characteristics of Study Population

#### Efficacy Outcomes

There were 550 participants in the study; of them, 275 each received roflumilast or placebo. The baseline clinical features of the population were equal in both groups, guaranteeing good comparability. The mean age was 65 years (40-85). Male to female distribution in participants was approximately 55:45 which is similar to COPD populations seen elsewhere.

The sample was 85% Caucasian, and the remainder of participants were African American (10%) or other ethnicities(5%). This distribution was similar between both treatment groups. Current or former smoking was a major feature, with 80% of individuals having smoked at some point and an average smoking history of 45 pack-years. The average body mass index (BMI) was 27 kg/m<sup>2</sup>, which classifies participants as being largely overweight to moderately obese.

The severity of COPD was graded according to the GOLD criteria (Stage 2 = moderate; Stage 3 = severe) and patients with stage-2 COPD represented more than half (%) in sample. Post-bronchodilator mean FEV1 was 50% predicted (SD =12%) The mean FEV1/FVC (forced vital capacity) ratio was

0.48, which reflected obstructive lung disease. The mean number of exacerbations which occurred during the past year was 3 (range )2-6) indicating a high-risk population for frequent future-exacerbation.

#### Improvements in Lung Function (FEV1):

The primary efficacy variable was the change in pre-bronchodilator FEV1 from baseline to 12 months of treatment. Among patients in the roflumilast group, there was a statistically significant change in FEV1 (from 137.3 to 148.5 versus from 138.8 to 139) vs placebo with no such improvement In the roflumilast group, the mean increase in FEV1 was 120 mL, compared with a mean change of 50 mL for placebo. The differences between the volume were 70 mL, with a confidence interval (CI) of 50 to 90 mL p <0.001 The improvement in FEV1 seen here points to reduced airway obstruction and improved lung function among those receiving roflumilast.

#### Reduction in Exacerbation Rates:

Roflumilast was also associated with a reduction in the occurrence of exacerbations of COPD. Annual exacerbations were 1.8 in the roflumilast group vs 2.5 among those receiving placebo Comparison of data analysis showed that there was a 28% reduction in exacerbation rate (rate ratio:0.72,95 % CI : 0.65 to 0.80; p <.001). This reduction is clinically important as frequent exacerbations are linked with more rapid disease progression, greater use of healthcare resources and worse quality of life.

#### Hospitalization Rates:

The number of hospitalisations for COPD exacerbations was also found to be much lower in the roflumilast group. Rate of COPD Exacerbations with Roflumilast Initially received (n = 3,091)Experienced at least one - or more (%) (RRR: relative risk reduction; % if CI)\*No. (%)Placebo Fever170/1,071 (19.9%)314/2,023 (15.5%)+33\*0Non-fatal MI31\*+30All-cause hospitalization545679CC death(lower limit -29%, p <.01 )CVD mortality including

CC171217SCAD208230(new State VSMISNewly definitions). These findings suggest that roflumilast may have the potential to reduce healthcare utilisation associated severe COPD exacerbations [18].

#### Safety and Tolerability

##### Adverse Events and Their Frequency:

Safety and tolerability of roflumilast were continuously monitored throughout the study. Gastrointestinal events (diarrhea [15%], nausea [10%], and abdominal pain [8%]) were the most common reported adverse reactions in the roflumilast arm. Weight loss (7%) and headache (5%) were other common adverse events. Those incidences in the placebo group were diarrhea (5%), nausea (4%) and abdominal pain (3%).

Significant adverse event included weight loss with a 2 kg reduction in average bodyweight over the total of 12 months compared to negligible change seen in placebo treated patients. The weight loss was modest and not related to malnutrition or other disease

##### Discontinuation Rates Due to Adverse Events:

Overall, the proportion of participants discontinuing because of adverse events was relatively low despite higher rates with roflumilast. However, the study drug was discontinued more frequently in the roflumilast group (10% of trial subjects) than in placebo-treated subjects (5%). Most frequently, patients in the roflumilast group discontinued because of gastrointestinal symptoms and weight loss. There was no evidence of any new or unanticipated safety findings and the adverse events observed were consistent with established roflumilast safety information.

##### Serious Adverse Events:

Serious adverse events (SAEs) were reported in 8% of participants in the roflumilast group and 10% in the placebo group. The most frequent SAEs were exacerbations of COPD requiring hospitalization. There were no significant differences in the overall

incidence of SAEs between the two groups. There were no deaths attributed to the study medication.

#### Subgroup Analyses

##### Patients with Chronic Bronchitis:

A pre-specified subgroup analysis was conducted to evaluate the efficacy of roflumilast in participants with chronic bronchitis, a common phenotype of COPD. In this subgroup, roflumilast demonstrated even greater benefits. Participants with chronic bronchitis in the roflumilast group had a mean increase in FEV1 of 150 mL compared to 60 mL in the placebo group (between-group difference of 90 mL,  $p < 0.001$ ). The exacerbation rate in this subgroup was reduced by 35% (rate ratio 0.65, 95% CI 0.55 to 0.77,  $p < 0.001$ ).

##### Impact of Smoking Status:

A final subgroup analysis investigated the effects of smoking status on therapeutic outcomes. Effect of Roflumilast in Current and Former Smokers: Quantitatively similar changes from baseline were reported for current smokers ( $p=0.015$ ) There was a trend toward greater improvement among former smokers but given the relatively small sample size this did not reach statistical significance Table 3. Change in FEV1 by smoking status Former smokers receiving roflumilast had a mean increase of 130 mL from baseline, compared with current smokers who experienced an improvement of only 100mL. Former smokers had a 30% reduction in exacerbation rates, and current smokers 25%, compared with participants not taking antibiotics. This would, therefore, infer that roflumilast helps provide improvement in lung function and a decrease exacerbation despite smoking history (though the benefit may be slightly greater as an ex-smoker) [19].

##### Effect of Baseline Severity:

The effect of baseline COPD severity on treatment outcomes was also assessed. Participants with more severe COPD (GOLD stage 3) showed substantial benefits from roflumilast. The mean increase in FEV1 in this subgroup was 140 mL, compared to 90 mL in participants with moderate COPD (GOLD

stage 2). Exacerbation rates were reduced by 32% in the severe subgroup and by 25% in the moderate subgroup. These results indicate that roflumilast is particularly beneficial for patients with more advanced disease [20].

#### Quality of Life Improvements:

Quality of life, measured using the St. George's Respiratory Questionnaire (SGRQ) and the COPD Assessment Test (CAT), improved significantly in the roflumilast group. The SGRQ total score decreased by 8 points in the roflumilast group compared to 3 points in the placebo group ( $p < 0.001$ ), indicating better health-related quality of life. The CAT scores showed a similar trend, with a mean reduction of 5 points in the roflumilast group versus 2 points in the placebo group ( $p < 0.01$ ). These improvements reflect a meaningful enhancement in participants' daily functioning and symptom management.

#### Conclusion

To summarize, the results of this study reveal a marked effectiveness of roflumilast as an intervention for COPD patients with moderate to severe severity compared to placebo. Time after time roflumilast demonstrated that it significantly improves lung function by virtue of marked improvements in FEV1 and considerable decrease in exacerbation rates and hospitalization. Although treatment was associated to some gastrointestinal side effects and a modest weight loss, safety and tolerability profile was largely adequate with a low

rate of discontinuation due to adverse events. Subgroup analyses confirmed the benefit of roflumilast according to whether patients had chronic bronchitis and use of other therapies, such as mucolytics (in those with chronic bronchitis), inhaled corticosteroids plus a LABA or severe airflow limitation among others. These results support a role of roflumilast as an effective addition to the armamentarium in COPD therapy, especially for high-risk patients towards exacerbations and progression. The results of the study provide powerful confirmation that it should be used in clinical practice, with a focus on how to help patients make informed decisions about care and get better health outcomes after being diagnosed as having moderate-to-severe COPD. Longer-term effects, combination therapies, and clarification of patient subgroups that benefit the most from roflumilast treatment qualitatively improved tailored therapy in COPD management are intriguing areas for future investigation.

#### REFERENCES:

- 1) A. H. and . E. J. M. , "The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease," *Pulmonary Pharmacology & Therapeutics*, vol. 23, no. 4, pp. 235-256, 2010.
- 2) N. A. P. P. and . L. A. H. P. , "Roflumilast: A Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease," *Clinical Therapeutics*, vol. 34, no. 1, pp. 56-66, 2012.
- 3) S. B. and . M. N. , "Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS," *International Immunopharmacology*, vol. 88, p. 106906, 2020.
- 4) J. A. W. M. "Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype," *CHEST*, vol. 143, no. 5, pp. 1302-1311, 2013.
- 5) W. B. W. M. "Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD," *CHEST*, vol. 144, no. 3, pp. 758-765, 2013.

- 6) T. V. "The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses," *Behavioural Brain Research*, vol. 303, pp. 26-33, 2016.
- 7) J. M. H. "Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial," *Pulmonary Pharmacology & Therapeutics*, vol. 21, no. 4, pp. 616-623, 2008.
- 8) E. v. S. M. "Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions," *Journal of Allergy and Clinical Immunology*, vol. 116, no. 2, pp. 292-298, 2005.
- 9) H.-J. K. "PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways," *Cellular Signalling*, vol. 20, no. 5, pp. 803-814, 2008.
- 10) P. B. "Roflumilast for asthma: Efficacy findings in mechanism of action studies," *Pulmonary Pharmacology & Therapeutics*, vol. 35, pp. S4-S10, 2015.
- 11) E. D. B. M. F. "Efficacy and safety of roflumilast in the treatment of asthma," *Annals of Allergy, Asthma & Immunology*, vol. 96, no. 5, pp. 679-686, 2006.
- 12) J. M. P. P. "Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease," *Journal of Allergy and Clinical Immunology*, vol. 134, no. 2, pp. 314-322.e9, 2014.
1. A. B. "Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study," *Neurobiology of Aging*, vol. 77, pp. 37-43, 2019.
2. B. X. "Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3 $\beta$ -mediated oxidative stress and IRE1 $\alpha$ /TRAF2/JNK pathway," *Free Radical Biology and Medicine*, vol. 163, no. 1, pp. 281-296, 2021.
- J. M. "Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD," *Pulmonary Pharmacology & Therapeutics*, vol. 28, no. 2, pp. 138-148, 2014.
- E. S. Zaki, "Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK/mTOR/ULK1-dependent autophagy pathway," *Life Sciences*, vol. 327, p. 121806, 2013.
- E. D. B. MD, "Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma," *Journal of Allergy and Clinical Immunology*, vol. 138, no. 1, pp. 142-149.e8, 2016.
- H. Feng, "Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice," *Laboratory Investigation*, vol. 97, no. 9, pp. 1008-1019, 2017.
- K. W. C. "Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats," *European Journal of Pharmacology*, vol. 571, no. 2-3, pp. 215-221, 2007.
- M. V. Duinen, "Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults," *Neuropharmacology*, vol. 131, pp. 31-38, 2018.

|                         |                        |                         |
|-------------------------|------------------------|-------------------------|
| Submission: 10-06-2026. | Acceptance: 11-08-2026 | Publication: 05-09-2026 |
|-------------------------|------------------------|-------------------------|

### Address for Correspondence:

**Dr. Muhammad Mudasir Saleem**, Paeds Department, CMH Lahore-Pakistan

**Cell:** +92 331 034 4336

**Email:** mudasirsaleem759@yahoo.com

